OBJECTIVE: To determine whether socioeconomic status (SES) influences the likelihood of antibiotic treatment of pulmonary exacerbations in patients with cystic fibrosis (CF). STUDY DESIGN: We used data on 9895 patients ≤ 18 years old from the Epidemiologic Study of CF. After establishing an individual baseline of clinical signs and symptoms, we ascertained whether antibiotics were prescribed when new signs/symptoms suggested a pulmonary exacerbation, adjusting for sex, presence of Pseudomonas aeruginosa, the number of new signs/symptoms, and baseline disease severity. RESULTS: In a 12-month period, 20.0% of patients <6 years of age, 33.8% of patients 6 to 12 years of age, and 41.4% of patients 13 to 18 years of age were treated with any (oral, intravenous (IV), or inhaled) antibiotics; the percentage receiving IV antibiotics was 7.3%, 15.2%, and 20.9%, respectively. SES had little effect on treatment for pulmonary exacerbation with any antibiotics, but IV antibiotics were prescribed more frequently for patients with lower SES. CONCLUSIONS: SES-related disparities in CF health outcomes do not appear to be explained by differential treatment of pulmonary exacerbations.
OBJECTIVE: To determine whether socioeconomic status (SES) influences the likelihood of antibiotic treatment of pulmonary exacerbations in patients with cystic fibrosis (CF). STUDY DESIGN: We used data on 9895 patients ≤ 18 years old from the Epidemiologic Study of CF. After establishing an individual baseline of clinical signs and symptoms, we ascertained whether antibiotics were prescribed when new signs/symptoms suggested a pulmonary exacerbation, adjusting for sex, presence of Pseudomonas aeruginosa, the number of new signs/symptoms, and baseline disease severity. RESULTS: In a 12-month period, 20.0% of patients <6 years of age, 33.8% of patients 6 to 12 years of age, and 41.4% of patients 13 to 18 years of age were treated with any (oral, intravenous (IV), or inhaled) antibiotics; the percentage receiving IV antibiotics was 7.3%, 15.2%, and 20.9%, respectively. SES had little effect on treatment for pulmonary exacerbation with any antibiotics, but IV antibiotics were prescribed more frequently for patients with lower SES. CONCLUSIONS: SES-related disparities in CF health outcomes do not appear to be explained by differential treatment of pulmonary exacerbations.
Authors: Gerald T O'Connor; Hebe B Quinton; Terry Kneeland; Richard Kahn; Thomas Lever; Joanne Maddock; Priscilla Robichaud; Mark Detzer; Donald R Swartz Journal: Pediatrics Date: 2003-04 Impact factor: 7.124
Authors: Don B Sanders; Julia Emerson; Clement L Ren; Michael S Schechter; Ronald L Gibson; Wayne Morgan; Margaret Rosenfeld Journal: Ann Am Thorac Soc Date: 2015-08
Authors: Robin S Everhart; Barbara H Fiese; Joshua M Smyth; Adrienne Borschuk; Ran D Anbar Journal: Pediatr Allergy Immunol Pulmonol Date: 2014-06-01 Impact factor: 1.349
Authors: Bradley S Quon; Kevin Psoter; Nicole Mayer-Hamblett; Moira L Aitken; Christopher I Li; Christopher H Goss Journal: Am J Respir Crit Care Med Date: 2012-09-13 Impact factor: 21.405
Authors: David C Taylor-Robinson; Rosalind L Smyth; Peter J Diggle; Margaret Whitehead Journal: Lancet Respir Med Date: 2013-01-30 Impact factor: 30.700